Pharmacological treatment options for hypertrophic cardiomyopathy: high time for evidence.
Hypertrophic cardiomyopathy (HCM) is the most common genetic heart disease, affecting over one million individuals in Europe. Hypertrophic cardiomyopathy patients often require pharmacological intervention for control of symptoms, dynamic left ventricular outflow obstruction, supraventricular and ventricular arrhythmias, and microvascular ischaemia. Current treatment strategies in HCM are predicated on the empirical use of long-standing drugs, such as beta-adrenergic and calcium blockers, although with little evidence supporting their clinical benefit in this disease. In the six decades since the original description of the disease, <50 pharmacological studies enrolling little over 2000 HCM patients have been performed, the majority of which were small, non-randomized cohorts. As our understanding of the genetic basis and pathophysiology of HCM improves, the availability of transgenic and preclinical models uncovers clues to novel and promising treatment modalities. Furthermore, the number of patients identified and followed at international referral centres has grown steadily over the decades. As a result, the opportunity now exists to implement adequately designed pharmacological trials in HCM, using established as well as novel drug therapies, to potentially intervene on the complex pathophysiology of the disease and alter its natural course. Therefore, it is timely to review the available evidence for pharmacological therapy of HCM patients, highlight the most relevant gaps in knowledge, and address some of the most promising areas for future pharmacological research, in an effort to move HCM into the era of evidence-based management.
Cardiothoracic and Vascular Department, Vita-Salute University, Milan, Italy. spoladore.roberto@hsr.it
Roberto
R
Spoladore
Martin S
MS
Maron
Rossella
R
D'Amato
Paolo G
PG
Camici
Iacopo
I
Olivotto
D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000188:drug therapy; D024741:Cardiomyopathy, Hypertrophic, Familial / Q000188:drug therapy* / Q000209:etiology; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D004353:Drug Evaluation, Preclinical; D004359:Drug Therapy, Combination; D019317:Evidence-Based Medicine; D005355:Fibrosis / Q000209:etiology; D006801:Humans; D009206:Myocardium / Q000473:pathology; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome; D014694:Ventricular Outflow Obstruction / Q000188:drug therapy
D000889:Anti-Arrhythmia Agents; D002317:Cardiovascular Agents